Best Research Podium Presentation Award

GENERAL (up to 3 awards each conference)

NEW INVESTIGATOR (up to 3 awards each conference)

STUDENT (up to 3 awards each conference)

Background provides appropriate perspective / context for the subject

Objectives / research questions are clearly stated

Research design / methods / modeling is appropriate and transparent {scores on this will determine winners in case of ties}

Data sources and/or sampling procedures are clear and appropriate

Research objectives are met/addressed

Factual information is kept separate from interpretations or implications

Abstract is presented in an unbiased manner

Clarity of presentation

All contributed podium presentations are considered for the awards.

3 weeks prior to conference, select preconference registrants are invited to participate to judge podium presentations

Judges are asked to select their field of interest

Judges are assigned presentations according to their field of interest

Each judge evaluates 1 presentation

All presentations are judged equally regardless of categories. Judges do not know whether the presentation is student, new investigator, or general

Judges' scores are compiled per category and analyzed

Committee chair(s) determine the recipients of the awards (up to 3 in each category)

A certificate with an inscription stating the award name, name of the author, and title of the presentation shall be sent to the award recipient after the conference when the conditions of acceptance are met.

To receive the award, the awardee must submit to the podium slide presentation / poster presentation for which the award is given for publication at the website, along with author permission. Failure to submit presentation slides and permission within the designated timeframe will result in forfeiture of award.

Official announcement of the recipients will occur after the conference via Value & Outcomes Spotlight, eBulletin, the website, and an email to conference attendees.

Best General Podium Presentations

Ashley Jaksa

Health Technology Assessment Agencies Consideration of Real-World Evidence [HT4]
Context Matters, New York, NY, USA

Erin Arthurs

Dolutegravir and Rilpivirine to Treat Virologically Suppressed Adults Living With HIV-1: A Canadian Cost-Utility Analysis [AV3]
GSK, Mississauga, ON, Canada

Louis P. Garrison

“It’s Tough to Make Predictions, Especially About the Future”: Comparing Life Expectancy Predictions Based on Period Versus Cohort Life Tables [VA3]
University of Washington, Seattle, WA, USA

Best Student Podium Research Presentations

Xue Han

Secondary Prevention Using Cholesterol-Lowering Medications in Patients Meeting New Treatment Guidelines: A Retrospective Cohort Analysis [CV2]
University of Southern California, Los Angeles, CA, USA

Xiaohan Hu

Trends in the Economic Value of Newly Approved Cancer Therapies in the US [VA2]
University of Southern California, Los Angeles, CA, USA

Francesco Saverio Mennin

Economic Consequences of Anti-HCV Antiviral Treatment Investment From the NHS Perspective [VA4]
Faculty of Economics, Centre for Economic and International Studies-Economic Evaluation and Health Technology Assessment, University of Rome Tor Vergata, Rome, Italy

Best New Investigator Podium Research Presentations

Nicolae Done

Comparative Effectiveness of Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation [CV3]
Veterans Health Administration, Boston, MA, USA

JA Voelker

Annual Change in Controlled Substance Opioid Prescribing and Concomitant Medications From an Urban Academic Emergency Department From 2011–2016 [HU1]
Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA

Christopher G Fawsitt

Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Duration in Genotype 1 Non-Cirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus [AV2]
University of Bristol, Bristol, UK

Best General Podium Presentations

Kristina Secnik Boye

PP4 - VALIDATION OF A QUESTIONNAIRE TO ASSESS PATIENT PERCEPTIONS OF INJECTION DEVICES FOR TYPE 2 DIABETES
Boye KS², Matza LS¹, Stewart KD¹, Paczkowski R², Currie BM¹, Yu R¹, Coyne KS¹, 
¹Evidera, Bethesda, MD, USA, ²Eli Lilly and Company, Indianapolis, IN, USA

Stephen S. Johnston

MD4 - COMPARISON OF ECONOMIC AND CLINICAL OUTCOMES BETWEEN THE DERMABOND® PRINEO® SKIN CLOSURE SYSTEM AND SKIN STAPLES IN PATIENTS UNDERGOING KNEE REPLACEMENT IN REAL WORLD CLINICAL PRACTICE
Johnston SS¹, Sutton N^2
1Johnson & Johnson Co., New Brunswick, NJ, USA, ²Ethicon Inc., Somerville, NJ, USA

Best Student Podium Research Presentations

Rahul Garg

CN2 - IMPACT OF DIFFUSE LARGE B-CELL LYMPHOMA ON VISITS TO DIFFERENT PROVIDER SPECIALTIES AMONG ELDERLY MEDICARE BENEFICIARIES: CHALLENGES FOR CARE COORDINATION
Garg R¹, Sambamoorthi U², Tan X², Basu SK³, Haggerty T¹, Kelly K^1
1West Virginia University, Morgantown, WV, USA, ²West Virginia University, School of Pharmacy, Morgantown, WV, USA, ³University of Louisville, Louisville, KY, USA

Weihsuan Lo-Ciganic

TP4 - GEOGRAPHIC VARIATION OF INAPPROPRIATE PRESCRIPTION OPIOID USE AMONG DISABLED MEDICARE BENEFICIARIES
Zhou L¹, Kwoh CK¹, Gellad WF², Donohue JM³, Roubal A⁴, Hines L⁵, Malone D¹, Bhattacharjee S¹, Lee JK¹, Lindermann J⁶, Bell M¹, Westra J¹, Lo-Ciganic W^1
1University of Arizona, Tucson, AZ, USA, ²Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, ³University of Pittsburgh, Pittsburgh, PA, USA, ⁴Robert Wood Johnson Foundation, Princeton, NJ, USA, ⁶Pharmacy Quality Alliance, Springfield, VA, USA, ⁶ESRI Inc., Broomfield, CO, USA

Yingnan Zhao

DB2 - RACIAL DISPARITY IN ACCESS TO NEWER CLASS ANTI-DIABETICS AMONG ADULT PATIENTS WITH DIABETES IN THE U.S.
Zhao Yo, Cooley K
Xavier University of Louisiana, New Orleans, LA, USA

Best New Investigator Podium Research Presentations

Lindsey E Falk

MD1 - COST EFFECTIVENESS OF THE LEFT ATRIAL APPENDAGE CLOSURE DEVICE COMPARED WITH ORAL ANTICOAGULANTS IN PATIENTS WITH NONVALVULAR ATRIAL FIBRILLATION
Falk LE¹, Wijeysundera HC², Sikich N¹, Dhalla I¹, Ng V^1
1Health Quality Ontario, Toronto, ON, Canada, ²Sunnybrook Health Sciences Centre, Toronto, ON, Canada

Chia-Te Liao

CV2 - ECONOMIC EVALUATION OF ALTERNATIVE ANTICOAGULANT DRUGS FOR THE PREVENTION OF STROKE AMONG 65-YEAR OLD ATRIAL FIBRILLATION PATIENTS IN TAIWAN
Liao C, Lee M
Chimei medical center, Tainan, Taiwan

Best General Podium Presentations

ME2 - MEDICARE PART D COST SHARING AND SPECIALTY DRUG INITIATION IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS

Doshi JA¹, Li P¹, Huo H¹, Pettit AR¹, Kumar R¹, Huntington SF², Weiss BM³¹University of Pennsylvania, Philadelphia, PA, USA, ²Yale University, New Haven, CT, USA, ³Hospital of the University of Pennsylvania, Philadelphia, PA, USA

CE2 - COST EFFECTIVENESS OF ADDING CLOSTRIDIAL COLLAGENASE OINTMENT TO STANDARD OF CARE IN INDIVIDUALS WITH STAGE IV PRESSURE ULCERS

Carter M¹, Gilligan A², Waycaster CR³, Schaum K⁴¹Strategic Solutions Inc., Cody, WY, USA, ²Truvan Health Analytics, Ann Arbor, MI, USA, ³Smith & Nephew Inc., Fort Worth, TX, USA, ⁴Smith & Nephew Inc., Lake Worth, FL, USA

The presentation described the cost effectiveness of adding an enzymatic debridement agent (clostridial collagenase ointment) to the standard of care given to individuals with stage IV pressure ulcers; this was the first data of its kind, which also demonstrated that this agent increases the cost effectiveness very substantially.

MA2 - HEALTH CARE EXPENDITURES ASSOCIATED WITH PERSISTENT EMERGENCY DEPARTMENT USE: A MULTI-STATE ANALYSIS OF MEDICAID BENEFICIARIES

Agarwal P¹, Bias T¹, Sambamoorthi U²¹West Virginia University, Morgantown, WV, USA, ²West Virginia University, School of Pharmacy, Morgantown, WV, USA

Best Student Podium Research Presentations

SY4 - ECONOMIC EVALUATION OF AN AUTOMATED RETINAL IMAGE ANALYSIS IN AUSTRALIAN ABORIGINAL AND TORRES STRAIT ISLANDER POPULATIONS FOR DETECTION OF DIABETIC RETINOPATHY

Ballreich J¹, Burnett A², Frick K¹, Ho A², Arkapaw L², Kleinert A^2
1Johns Hopkins University, Baltimore, MD, USA, ²Brien Holden Vision Institute and Vision Cooperative Research Centre, Sydney, Australia

We evaluated the use of an automated retinal image analysis screening method for detection of diabetic retinopathy in the Indigenous Australian population, and our results demonstrated significant costs savings under a variety of technical assumptions.

BI2 - ESTIMATING THE COSTS OF SUPPORTING SAFETY-NET TRANSFORMATION INTO PATIENT-CENTERED MEDICAL HOMES IN POST-KATRINA NEW ORLEANS

Camponeschi GF¹, Bridges JF², Danoff SK¹, Richardson B¹
Shao H¹, Shi L¹, Diana M¹, Brown L², Mason K², Cocran D², Carruth A², Schmidt L^3
1Tulane University, New Orleans, LA, USA, ²Louisiana Public Health Institute, New Orleans, LA, USA, ³University of California at San Francisco, San Francisco, CA, USA

Our study further addressed the difficulty for a safety-net clinic to transform into a patient-centered medical home (PCMH) without external funding, and our results provided monetary inference for the future policy which intend to support PCMH transformation among safety-net clinics.

CO3 - COMPARATIVE EFFECTIVENESS OF PANITUMUMAB VERSUS CETUXIMAB IN PATIENTS WITH CHEMO-REFRACTORY WILD-TYPE KRAS METASTATIC COLORECTAL CANCER

Xu Y, Hay JW, Barzi A
University of Southern California, Los Angeles, CA, USA

It is a good case study which shows that specialty drugs with similar clinical efficacy may differ in other factors, such as administration schedule, toxicity and its treatment cost, quality of life, and thus providing overall advantage on top of clinical benefit.

Best New Investigator Podium Research Presentations

CN1 - THE POTENTIAL CLINICAL, RESOURCE USE, AND FISCAL IMPACTS OF LUNG-RADS TO INFORM LUNG CANCER SCREENING IN MEDICARE

Roth J¹, Sullivan SD², Ramsey S¹, Goulart B^1
1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA

Our simulation modeling study demonstrated that over a 3-year period for Medicare eligible patients, full adoption of Lung-RADS to manage lung cancer screening is expected to produce 0.5 to 1 million fewer false-positive screening results, 5,000 to 11,000 fewer invasive diagnostic follow-up procedures, and direct medical expenditure savings of $128 to $256 million. These findings suggest that nuanced lung cancer screening management systems can have important clinical, resource use, and fiscal impacts in addition to reducing physical and psychological harms from false-positive screening results.

CV2 - EFFECTIVENESS AND SAFETY OF REDUCED DOSE NON-VITAMIN K ANTAGONIST ORAL ANTICOAGULANTS IN PATIENTS WITHOUT SEVERE RENAL IMPAIRMENT

Yao X, Shah ND, Sangaralingham LR, Gersh BJ, Noseworthy PA
Mayo Clinic, Rochester, MN, USA

In routine clinical practice, one in eight patients with no renal indication for dose reduction received a reduced-dose novel oral anticoagulant (NOAC), which may be associated with reduced effectiveness in stroke prevention without any improvement in safety in patients treated with apixaban.

PR2 - GENERIC INJECTABLE SHORTAGES AND TRENDS IN AVERAGE SALES PRICE IN THE UNITED STATES

Hur P¹, Ray D², Vegesna A³, Obi EN^2
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Rutgers University, Piscataway, NJ, USA, ³Jefferson College of Population Health, Philadelphia, PA, USA

This study examined trends of Average Sales Price for Medicare Part B generic sterile injectables on shortage in order to assist pharmacy budget management.

Best General Podium Presentations

PP2 - PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA¹, Poulos C¹, Hackshaw MD², Pugh A¹, Jobanputra MH^2
1RTI Health Solutions, Research Triangle Park, NC, USA, ²GlaxoSmithKline, Philadelphia, PA, USA

CP4 - GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I¹, Balk E¹, Wong JB², Trikalinos TA^1
1Brown University, Providence, RI, USA, ²Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

DB4 - DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM¹, Lamerato L², Dalal M³, Sung JC³, Khan I³, Jhaveri M³, Koren A³, Schulman KL^4
1Harvard Medical School, Boston, MA, USA, ²Henry Ford Health System, Detroit, MI, USA, ³Sanofi US, Inc., Bridgewater, NJ, USA, ⁴Outcomes Research Solutions, Inc., Bolton, MA, US

Best Student Podium Research Presentations

HT2 - APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K¹, Basu A², Hansen RN¹, Watkins J³, Sullivan SD^2
1School of Pharmacy, University of Washington, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Premera Blue Cross, Mountlake Terrace, WA, USA

PP4 - MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF¹, Bridges JF², Danoff SK¹, Richardson B^1
1Johns Hopkins University, Baltimore, MD, USA, ²John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

CS1 - US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

Best New Investigator Podium Research Presentations

CV4 - OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A¹, King J¹, Singhal M¹, Brixner D¹, Kielhorn A², Patel H², Maya J², Biskupiak JE¹, Munger M^1
1University of Utah, Salt Lake City, UT, USA, ²Amgen, Thousand Oaks, CA, USA

CS2 - ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3 - URE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M¹, Bansal A², Koepl L¹, Wagner S³, Ramsey S^1 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Bristol-Myers Squibb, Washington Crossing, PA, USA

Best General Podium Presentations

PP2 - PATIENT PREFERENCES FOR FIRST-LINE MAINTENANCE TREATMENTS FOR OVARIAN CANCER

Mansfield CA¹, Poulos C¹, Hackshaw MD², Pugh A¹, Jobanputra MH^2
1RTI Health Solutions, Research Triangle Park, NC, USA, ²GlaxoSmithKline, Philadelphia, PA, USA

CP4 - GUIDANCE FOR THE CONDUCT AND REPORTING OF MODELING AND SIMULATION IN THE CONTEXT OF HEALTH TECHNOLOGY ASSESSMENT

Dahabreh I¹, Balk E¹, Wong JB², Trikalinos TA^1
1Brown University, Providence, RI, USA, ²Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA

DB4 - DEVELOPMENT AND VALIDATION OF ALGORITHMS TO IDENTIFY STATIN INTOLERANCE IN A US ADMINISTRATIVE DATABASE

Foody JM¹, Lamerato L², Dalal M³, Sung JC³, Khan I³, Jhaveri M³, Koren A³, Schulman KL^4
1Harvard Medical School, Boston, MA, USA, ²Henry Ford Health System, Detroit, MI, USA, ³Sanofi US, Inc., Bridgewater, NJ, USA, ⁴Outcomes Research Solutions, Inc., Bolton, MA, US

Best Student Podium Research Presentations

HT2 - APPLICATION OF COST-EFFECTIVENESS LOGIC TO US MANAGED CARE DRUG FORMULARIES: LONG TERM OUTCOMES OF A VALUE-BASED FORMULARY

Yeung K¹, Basu A², Hansen RN¹, Watkins J³, Sullivan SD^2
1School of Pharmacy, University of Washington, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Premera Blue Cross, Mountlake Terrace, WA, USA

PP4 - MEASURING TREATMENT PREFERENCES OF PATIENTS DIAGNOSED WITH IDIOPATHIC PULMONARY FIBROSIS USING BEST-WORST SCALING

Camponeschi GF¹, Bridges JF², Danoff SK¹, Richardson B^1
1Johns Hopkins University, Baltimore, MD, USA, ²John Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

CS1 - US BASED DRUG COST PARAMETER ESTIMATES USING NATIONAL AVERAGE DRUG ACQUISITION COST

Levy JF, Rosenberg MA, Vanness DJ
University of Wisconsin-Madison, Madison, WI, USA

Best New Investigator Podium Research Presentations

CV4 - OUTCOMES AND HEALTH RESOURCE UTILIZATION AMONG PATIENTS WITH HEART FAILURE WITH REDUCED EJECTION FRACTION (HFREF) AT AN ACADEMIC MEDICAL CENTER (AMC) IN THE UNITED STATES

Bress A¹, King J¹, Singhal M¹, Brixner D¹, Kielhorn A², Patel H², Maya J², Biskupiak JE¹, Munger M^1
1University of Utah, Salt Lake City, UT, USA, ²Amgen, Thousand Oaks, CA, USA

CS2 - ECONOMIC MODELLING IN RANDOMIZED CONTROLLED TRIAL (RCT)-BASED ECONOMIC EVALUATIONS: EMPIRICAL EXAMPLES OF ITS EFFECT ON THE PRECISION OF ECONOMIC AND DECISION OUTCOMES

Nam J, Berry C, Henderson R, Briggs A
University of Glasgow, Glasgow, UK

CS3 - URE MODELS: ACCOUNTING FOR CURED PATIENTS IN ECONOMIC EVALUATIONS

Othus M¹, Bansal A², Koepl L¹, Wagner S³, Ramsey S^1 1Fred Hutchinson Cancer Research Center, Seattle, WA, USA, ²University of Washington, Seattle, WA, USA, ³Bristol-Myers Squibb, Washington Crossing, PA, USA

Best General Podium Presentations

CA1 - BREAST CANCER PATIENTS RECEIVING GUIDELINE-CONCORDANT ADJUVANT THERAPY REGIMENS HAVE BETTER ALL-CAUSE AND DISEASE-SPECIFIC SURVIVAL: NEW FINDINGS FROM RURAL GEORGIA

Lipscomb J¹, Guy GP², Gillespie T³, Goodman M¹, Richardson LC², Ward KC^1
1Emory University, Rollins School of Public Health, Atlanta, GA, USA, ²Centers for Disease Control and Prevention, Atlanta, GA, USA, ³Emory University School of Medicine, Atlanta, GA, USA

CA3 - TREATMENT PATTERNS AFTER CASTRATION RESISTANT PROSTATE CANCER (CRPC) DIAGNOSIS: A EUROPEAN PHYSICIAN SURVEY

Pokras SM¹, Zyczynski TM², Lees M³, Jiao X¹, Blanchette C¹, Powers J^4
1IMS Health, Alexandria, VA, USA, ²Bristol-Myers Squibb, Princeton, NJ, USA, ³Bristol-Myers Squibb, Rueil-Malmaison, France, ⁴University of Colorado, Denver, Aurora, CO, USA

SB2 - MEDICAL, DRUG, AND WORK-LOSS COSTS OF DIABETIC FOOT ULCERS

Rice JB¹, Desai U¹, Cummings AK¹, Birnbaum HG¹, Skornicki M², Parsons N^2
1Analysis Group, Inc., Boston, MA, USA, ²Organogenesis Inc., Canton, MA, USA

Best Student Podium Research Presentations

DU4 - THE ASSOCIATION OF BURN INJURIES AND PSEUDOEPHEDRINE SALES

Goodin AJ, Perin NR, Freeman PR, Talbert J, Wittmer D, Blumenschein K
University of Kentucky, Lexington, KY, USA

MD2 - SKELETAL-RELATED EVENTS AND MORTALITY AMONG SEER-MEDICARE PATIENTS WITH METASTATIC PROSTATE CANCER: THE IMPLICATIONS OF MEASUREMENT APPROACH

Onukwugha E¹, Yong C¹, Mullins CD¹, Seal B², Hussain A^3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, ²Bayer HealthCare Pharmaceuticals, Inc., Pine Brook, NJ, USA, ³University of Maryland School of Medicine, Baltimore, MD, USA

MD3 - ASSOCIATION BETWEEN INHALED ANTICHOLINERGICS USE AND ALL-CAUSE MORTALITY AMONG ELDERLY MEDICARE BENEFICIARIES WITH RESPIRATORY DISEASES

Ajmera MR¹, Pan X¹, Findley P², Rust G³, Sambamoorthi U^4
1West Virginia University, Morgantown, WV, USA, ²Rutgers University, New Brunswick, NJ, USA, ³Morehouse School of Medicine, Atlanta, GA, USA, ⁴West Virginia University School of Pharmacy, Morgantown, WV, USA

Best New Investigator Podium Research Presentations

HT1 - INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES

Nicod E, Kanavos P
London School of Economics and Political Science, London, UK

RM2 - USE OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS, ANGIOTENSIN RECEPTOR BLOCKERS AND RISK OF DEMENTIA IN HEART FAILURE

Chitnis AS¹, Johnson ML², Aparasu RR², Chen H², Kunik ME³, Schulz PE^4
1United BioSource Corporation, Lexington, MA, USA, ²University of Houston, Houston, TX, USA, ³Michael E. DeBakey Veterans Affairs Medical Center (MEDVAMC), Houston, TX, USA, ⁴The University of Texas Health Science Center at Houston, Houston, TX, US

RM3 - SULFONYLUREAS ARE ASSOCIATED WITH ELEVATED RISK OF HIP FRACTURES AMONG ELDERLY MEN AND WOMEN WITH TYPE-2 DIABETES

Rajpathak SN¹, Fu C¹, Engel SS¹, Brodovicz KG¹, Lapane K^2
1Merck & Co, North Wales, PA, USA, ²University of Massachussets, Worcester, MA, USA

Best General Podium Presentations

Victoria Allan

Cv2: Impact Of Atrial Fibrillation (Af) Awareness Campaigns On Rates Of Af Related Consultations In Uk Primary Care: Interrupted Time Series Analyses

James Signorovitch

Nd1: Ambulatory Function In Duchenne Muscular Dystrophy (Dmd): The Characteristic Trajectory And Variation Across Individuals

Richard Macaulay

Ht4: Pan-European Hta – Where We Have Been, Where We Are Going?

Ilse Van Oostrum

Mo4: Comparing Mixture Cure Models With Standard Parametric Models Within Three- And Five-State Partition Survival Frameworks

Best Student Podium Research Presentations

Olivia Dong

Cv1: A Cost-Effectiveness Analysis Of Muliti-Gene Pharmacogenetic Testing In Acute Coronary Syndrome Patients Following Percutaneous Coronary Intervention

Baptiste Leurent

Rm1: Sensitivity Analysis For Not-At-Random Missing Data In Trial-Based Cost-Effectiveness Analysis Using Multiple Imputation

Marguerite Kandel

Ql4: Assessment Of Quality Of Life In Patients With Metastatic Melanoma In Real Clinical Practice In France

Best New Investigator Podium Research Presentations

Vivian J Peirce

Md1: Evidence Development Timeline Of Medical Devices In The Uk: Where Do Medical Innovation Briefings Fit?

Christoph Klapproth

Ql1: Validation Of Promis Preference Score (Propr) In German Patients With Rheumatological Conditions

Carlijn Hintzen

Ht2: Patient Centric Measures In Htas For Autoimmune Diseases

Best General Podium Presentations

AD4: PREDICTIVE ANALYSIS FOR IDENTIFYING PATIENT CHARACTERISTICS ASSOCIATED WITH PRIMARY MEDICATION NONADHERENCE FOR LIPID LOWERING THERAPIES

Pallavi B. Rane
Amgen Inc., Thousand Oaks, CA, USA

SY1: PSORIASIS DRUGS IN EUROPE - MARKET ACCESS DECISIONS IN COMPARISON BASED ON THE PRISM ACCESS DATABASE

Lutz Vollmer
MArS- Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany

AD1: EXPLORING FACTORS EXPLAINING TREATMENT ACCEPTANCE IN PATIENTS SUFFERING FROM A CHRONIC DISEASE

Elodie de Bock
Mapi, Patient Centered Outcomes, Lyon, France

Best Student Podium Research Presentations

IN4: COST-EFFECTIVENESS OF ADDITIONAL VACCINATION OF BOYS AGAINST HPV IN GERMANY

Oliver Damm
School of Public Health, Bielefeld University, Bielefeld, Germany

CV2: A FRAMEWORK FOR THE COST-EFFECTIVENESS ANALYSIS OF NOVEL BIOMARKER TESTING IN CARDIOVASCULAR DISEASE

Ciaran N. Kohli-Lynch
University of Glasgow, Glasgow, UK

IN2: COST-EFFECTIVENESS AND MODELING APPROACHES OF DIRECT-ACTING ANTIVIRAL AGENTS IN CHRONIC HEPATITIS C INFECTION: A SYSTEMATIC LITERATURE REVIEW

László Szilberhorn
Eötvös Loránd University (ELTE), Budapest, Hungary

Best New Investigator Podium Research Presentations

AD3: FACTORS ASSOCIATED WITH AN ADHERENCE WITH ANTIEPILEPTIC DRUGS IN CHILDREN TREATED IN PEDIATRIC PRACTICES IN GERMANY

Silvia Dombrowski
QuintilesIMS, Frankfurt am Main, Germany

PP2: CHOICE OF INSTRUMENT IMPACTS HEALTHCARE DECISIONS: EFFECT OF SOURCE OF UTILITY DERIVED FROM THE SAME PATIENT POPULATION ON COST-EFFECTIVENESS

Necdet B. Gunsoy
GSK, Uxbridge, UK

PP1: MIMICKING REAL LIFE DECISION-MAKING IN HEALTH: ALLOWING RESPONDENTS TIME-TO-THINK IN A DISCRETE CHOICE EXPERIMENT

J Veldwijk
Erasmus University Rotterdam, Rotterdam, The Netherlands

Best General Podium Presentations

HT1-ALIGNED AND FLEXIBLE? A COMPARATIVE REVIEW OF SMC AND NICE DECISION-MAKING

Johnson H¹, Spoors J², Johnson J^1
1Helen Johnson Consulting Ltd, Welwyn Garden City, UK, ²RJW & Partners, Royston, UK

AD3-MEDICATION ADHERENCE AND PERSISTANCE IN TYPE 2 DIABETES MELLITUS (T2DM): PATIENTS PERSPECTIVE IN THE SPANISH HEALTH CARE SYSTEM

Labrador Barba E¹, Hernandez Mijares A², Alonso Moreno FJ³, Rodriguez de Miguel M¹, Orera Peña ML¹, Aceituno Mata S⁴, Perez L⁴, Faus Dader MJ^5
1Mylan, Barcelona, Spain, ²Dr. Peset Hospital, Valencia, Spain, ³Sillería Health Center, Toledo, Spain, ⁴Outcomes’10, Castellon, Spain, ⁵Faculty of Pharmacy, Granada, Spain

A patient-centered research about the factors and strategies which diabetes patients consider important for their treatment adherence. Our results could help health professionals to improve poor adherence management by the incorporation of patients’ opinions and preferences.

DB1-MORTALITY EXCESS DUE TO CLOSTRIDIUM DIFFICILE INFECTION - A NATIONAL DATABASE ANALYSIS

Bouee S¹, Levy Bachelot L², Ravonimbola H², Longepierre L¹, Godard C², Gourmelen J³, Barbut F⁴

¹CEMKA, Bourg La Reine, France, ²MSD France, Courbevoie, France, ³UMS 011 - Inserm - UVSQ, Villejuif, France, ⁴Laboratory for Clostridium Difficile, Paris, France

Best Student Podium Research Presentations

ND1-BURDEN AND WORK PRODUCTIVITY LOSS IMPAIRMENT FROM PROVIDING CARE TO ALZHEIMER'S DISEASE PATIENTS

Hu X¹, Ritchie C², Wood R³, Jones E³, Black CM⁴, Khandker RK⁴, Ambegaonkar BM^4
1University of Southern California, Los Angeles, CA, USA, ²University of Edinburgh, Edinburgh, UK, ³Adelphi Real World, Bollington, UK, ⁴Merck & Co., Inc., Rahway, NJ, USA

PP1-NINE TESTS FOR ASSESING VALIDITY OF A DISCRETE-CHOICE EXPERIMENT

Janssen EM, Bridges JF
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

DB4-USE OF DATA-MINING TO PERFORM A REAL WORLD COST ANALYSIS OF HER2-POSITIVE BREAST CANCER IN IRAN

Ansaripour A¹, Zendehdel K², Tadayon N³, Sadeghi F⁴, Uyl-de Groot C⁵, Redekop WK^6
1Erasmus University Rotterdam, Rotterdam, The Netherlands, ²Tehran Medical Sciences and Medical Education University, Tehran, Iran, ³Shahid Beheshti University of Medical Sciences, Tehran, Iran (Islamic Republic of), ⁴Tehran Medical Sciences and Medical education University, Tehran, Iran, ⁵National Health Care Institute, Diemen, The Netherlands, ⁶National University of Singapore, Singapore, Singapore

Best New Investigator Podium Research Presentations

HT6-CRITERIA DRIVING VALUES ASSESSMENTS IN MULTIPLE SCLEROSIS MEDICINES

Visintin E¹, Kanavos P^2
1London School of Economics and Political Sciences, London, UK, ²London School of Economics and Political Science, London, UK

EE2-IS IT REALLY COST-EFFECTIVE TO RISK-ASSESS ALL HOSPITALIZED PATIENTS FOR PRESSURE ULCERS EVERY NURSING-SHIFT?

Padula WV¹, Onyekwere U¹, Makic MB², Wald HL², Epstein Z³, Meltzer DO^4
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, ²University of Colorado, Aurora, CO, USA, ³Pomona College, Claremont, CA, USA, ⁴University of Chicago, Chicago, IL, USA

PP3-PATIENTS' PREFERENCES FOR CHARACTERISTICS OF PERIODONTAL DISEASE AND ITS' TREATMENT: A DISCRETE CHOICE EXPERIMENT

Vennedey V¹, Danner M¹, Civello D¹, Schwalm A², Seidl A², Hiligsmann M³, Stock S^1
1University Hospital Cologne, Cologne, Germany, ²Institute for Quality and Efficiency in Health Care (IQWiG), Cologne, Germany, ³Maastricht University, Maastricht, The Netherlands

Best General Podium Presentations 

CA1 - ANALYSIS OF THE RELATIONSHIP BETWEEN PATIENT-REPORTED OUTCOMES (PROS) AND CLINICAL OUTCOMES IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PATIENTS WITHOUT PRIOR CHEMOTHERAPY

Traina S¹, Li T¹, Johnson K¹, Ho KF², Molina A³, Cella D^4
1Janssen Research & Development, Raritan, NJ, USA, ²STAT-TU Inc., Toronto, ON, Canada, ³Janssen Research & Development, Menlo Park, CA, USA, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, USA

EA2 - ACCESS TO INNOVATIVE DRUGS IN PATIENTS WITH METASTATIC LUNG CANCER IN FRENCH PUBLIC HOSPITALS (THE TERRITOIRE STUDY)

Scherpereel A¹, Fernandes J², Cotté F³, Blein C⁴, Debieuvre D⁵, Durand-Zaleski I⁶, Gaudin A³, Ozan N³, Saitta B⁴, Souquet P⁷, Vainchtock A⁴, Westeel V⁸, Chouaïd C^9
1CHU Lille, Lille, France, ²Oc Santé, Montpellier, France, ³Bristol-Myers Squibb, Rueil-Malmaison, France, ⁴HEVA, Lyon, France,⁵Mulhouse Hospital, Mulhouse, France, ⁶URC Eco, Paris, France, ⁷Hospices Civils de Lyon, Lyon, France, ⁸Besançon Hospital, Besançon, France, ⁹CHIC, Créteil, France

PR2 - PREDICTING POST-AMNOG REBATE OUTCOMES FOR ONCOLOGY DRUGS

Subramanian D, Lazaro V
Qlaar Pte. Ltd., Singapore, Singapore

Best Student Podium Research Presentations

PR1 - DETERMINANTS OF ORPHAN DRUG PRICES IN FRANCE: REGRESSION ANALYSIS

Korchagina D¹, Vataire A², Toumi M³, Falissard B⁴, Aballéa S^2
1University of Paris-Sud, Paris, France, ²Creativ-Ceutical, Paris, France, ³Aix-Marseille University, Marseille, France, ⁴Maison de Solenn, Paris, France

EA4 - ORPHAN DESIGNATIONS AND APPROVALS IN THE EU, UNITED STATES AND JAPAN

Korchagina D¹, Tomita N², Falissard B³, Toumi M⁴, Tavella F^5
1University of Paris-Sud, Paris, France, ²National Institute of Public Health, Saitama, Japan, ³Maison de Solenn, Paris, France,⁴Aix-Marseille University, Marseille, France, ⁵Creativ-Ceutical, London, UK

RM8 - COMPARISON OF TIMED AUTOMATA WITH DISCRETE EVENT SIMULATION FOR MODELING PERSONALIZED TREATMENT DECISIONS: THE CASE OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER

Degeling K, Koffijberg H, Schivo S, Langerak R, IJzerman MJ
University of Twente, Enschede, The Netherlands

Best New Investigator Podium Research Presentations

VA3 - ECONOMIC EVALUATION OF CHILDREN VACCINATION FROM 2 TO 18 YEARS OF AGE WITH THE LIVE ATTENUATED INFLUENZA VACCINE COMPARED WITH THE EXISTING VACCINES IN THE PORTUGUESE SETTING

Ferreira J¹, Trindade R¹, Norte J¹, Sackeyfio A^2
1Astrazeneca Produtos Farmacêuticos Lda., Lisboa, Portugal, ²AstraZeneca Alderley House, Alderley Park, UK

MD4 - COST-EFFECTIVENESS OF 18F-FDG PET/CT FOR SCREENING DISTANT METASTASIS IN STAGE II/III BREAST CANCER PATIENTS OF THE UK, THE UNITED STATES AND THE NETHERLANDS

Miquel-Cases A¹, Teixeira S¹, Retèl V¹, Steuten L², Valdés Olmos R¹, Rutgers E¹, van Harten WH^1
1Netherlands Cancer Institute, Amsterdam, The Netherlands, ²University of Washington and Panaxea bv, Seattle, WA, USA

CA3 - THE BURDEN OF CANCER IN EMERGING ECONOMIES: PRODUCTIVITY LOSS AS AN ALTERNATIVE PERSPECTIVE

Pearce A¹, Hanly P², Sharp L³, Soerjomataram I^4
1National Cancer Registry Ireland, Cork, Ireland, ²National College of Ireland, Dublin, Ireland, ³Newcastle University, Newcastle, UK, ⁴International Agency for Research on Cancer, Lyon, France

CE1-CLINICAL OUTCOMES AND COST-EFFECTIVENESS OF NOVEL ORAL ANTICOAGULANTS INCORPORATING REAL-WORLD ELDERLY PATIENTS WITH ATRIAL FIBRILLATION

Zhao YJ¹, Lin L¹, Zhou HJ¹, Khoo AL¹, Tan KT², Chew AP³, Foo CG⁴, Oh CT⁵, Lim WS³, Lim BP^1
1Pharmacy and Therapeutics Office, Group Corporate Development, National Healthcare Group, Singapore, Singapore, ²Department of Pharmacy, Tan Tock Seng Hospital, Singapore, Singapore, ³Department of Geriatric Medicine, Tan Tock Seng Hospital, Singapore, Singapore, ⁴Department of Cardiology, Tan Tock Seng Hospital, Singapore, Singapore, ⁵Department of Neurology, National Neuroscience Institute, Singapore, Singapore, Singapore

RM4-RELIABILITY AND VALIDITY OF THE HEALTH ASSESSMENT QUESTIONNAIRE (HAQ) IN PATIENTS WITH SPONDYLOARTHRITIS

Kwan YH¹, Yong ST², Fong W², Lui NL², Malhotra R¹, Thumboo J³, Ostbye T^1
1Duke-NUS Medical School, Singapore, Singapore, ²Singapore General Hospital, Singapore, Singapore, ³Singhealth, Singapore, Singapore

RM3-COMPARISON OF CAREGIVER-RATED 3-LEVEL EUROQOL-5D (EQ-5D-3L) AND HEALTH UTILITIES INDEX MARK 3 (HUI3) IN PATIENTS WITH DEMENTIA IN SINGAPORE

Wang VW¹, Kandiah N², Lin X², Wee HL^1
1National University of Singapore, Singapore, Singapore, ²National Neuroscience Institute, Singapore, Singapore

HC4-DERIVATION AND EXTERNAL VALIDATION OF AN EARLY READMISSION RISK PREDICTION MODEL

Dorajoo SR¹, See V¹, Chan CT¹, Tan ZY², Koomanan N³, Ong TT⁴, Razak SM⁴, Yap CW¹, Chan A^1
1National University of Singapore, Singapore, Singapore, ²Khoo Teck Puat Hospital, Singapore, Singapore, ³Singapore General Hospital, Singapore, Singapore, ⁴Temasek Polytechnic, Singapore, Singapore

CU3-LIFE EXPECTANCY, QUALITY-ADJUSTED LIFE YEARS, AND TOTAL LIFETIME COSTS FOR AUSTRALIAN PEOPLE WITH MULTIPLE SCLEROSIS

Palmer AJ, Taylor B, Van der Mei I, Si L, Ahmad H
University of Tasmania, Hobart, Australia

IN3-EFFECTS OF HBSAG POSITIVITY DURING PREGNANCY ON ADVERSE MATERNAL OUTCOMES: A RETROSPECTIVE DATABASE ANALYSIS

Tan J¹, Sun X², Liu X^3
1School of West China Public Health, Sichuan University, Chengdu, China, ²West China Hospital of Sichuan University, Chengdu, China, ³No. 2 West China Hospital of Sichuan University, Chengdu, China

RR3 - AWARNESS AND PREVENTION OF CHRONIC DISEASES IN JAPAN

Gupta S¹, Fukuda T², Stankus AP^1
1Kantar Health, Princeton, NJ, USA, ²National Institute of Public Health, Saitama, Japan

CV4 - DOES THE CURRENT RECOMMENDED TARGET LDL GOAL IMPROVE SURVIVAL FOR ACUTE CORONARY SYNDROME PATIENTS IN HONG KONG?

Lee VW, Chau R, Cheung H, Yu CM, Lam YY, Yan BP
The Chinese University of Hong Kong, Shatin, Hong Kong, China

IN2 - EFFECT OF VACCINATION AGE ON COST-EFFECTIVENESS OF HUMAN PAPILLOMAVIRUS VACCINATION AGAINST CERVICAL CANCER IN CHINA

Liu Y, Zhang Q, HU S, Zhao F
Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

CV2 - MANAGEMENT OF ISCHAEMIC STROKE PATIENTS ENROLLED IN THE JAPAN STROKE DATABANK (JSD)

Murteira S¹, Toumi M², Dorey J³, Dabbous FM⁴, Kobayashi S^5
1Lundbeck Japan KK, Tokoyo, Japan, ²University Claude Bernard Lyon 1, Lyon, France, ³Creativ-Ceutical USA, Chicago, IL, USA,⁴University of Illinois at Chicago, Chicago, IL, USA, ⁵Shimane University, Matsue-shi, Japan

DB2 - EFFICACY AND SAFETY OF HUMAN INSULIN VERSUS ANIMAL INSULIN AMONG PATIENTS WITH DIABETES IN CHINA: A META-ANALYSIS

Zhang HN¹, Wang K², Yang J², Liu L^2
1China Pharmaceutical University, Nanjing, China, ²Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China

CV3 - ECONOMIC EVALUATION OF CHANGE IN REIMBURSEMENT CRITERIA FOR LIPID-LOWERING DRUGS IN TAIWAN

Wu GH¹, Wang Y², Pwu R^2
1Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, and Department of Physical Therapy and Assistive Technology, National Yang-Ming University, Taipei, Taiwan, ²Division of Health Technology Assessment, Center for Drug Evaluation, National Institute of Health Technology Assessment, Taipei, Taiwan

CN1 - STATINS AND THE RISK OF HEPATOCELLULAR CARCINOMA IN PATIENTS WITH HEPATITIS B VIRUS INFECTION

Tsan Y¹, Lee C¹, Wang J², Chen P^1
1National Taiwan University, Taipei, Taiwan, ²National Cheng Kung University College of Medicine, Tainan, Taiwan

CN2 - HOW EARLY-STAGE NON-PERSISTENCE AND NON-ADHERENCE TO ADJUVANT HORMONAL THERAPY ASSOCIATED WITH POSTMENOPAUSAL BREAST CANCER MORTALITY IN TAIWAN

Hsieh KP¹, Chen LC², Chang CS¹, Yang YH^1
1Kaohsiung Medical University, Kaohsiung, Taiwan, ²University of Nottingham, Nottingham, UK

CN4 - INPATIENT TREATMENT PATTERNS AND HEALTHCARE EXPENDITURES FOR HEPATOCELLULAR CARCINOMA AMONG POPULATION WITH URBAN BASIC HEALTH INSURANCE IN CHINA

Xiong X¹, Li J¹, Qiao Y², Yu Z³, Zhang YJ⁴, Meng, W¹, Zhang J^1
1China Health Insurance Research Association, Beijing, China, ²Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ³Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, ⁴Sino-American Shanghai Squibb Pharmaceuticals Ltd., Shanghai, China

CL3 - ANTICOAGULATION CONTROL OF A PHARMACIST MANAGED ANTICOAGULATION CLINIC IN A NATIONAL REFERRAL CENTRE IN MALAYSIA

Thanimalai S¹, Shafie AA¹, Ahmad Hassali MA¹, Sinnadurai J^2
1Universiti Sains Malaysia, Penang, Malaysia, ²Hospital Kuala Lumpur, Kuala Lumpur, Wilayah Persekut, Malaysia

PR3 - UTILITY VALUES FOR CHEMOTHERAPY-RELATED ADVERSE EVENTS: A REVIEW OF THE LITERATURE

Shabaruddin FH¹, Chen LC², Elliott R², Payne K^3
1University of Malaya, Kuala Lumpur, Malaysia, ²University of Nottingham, Nottingham, UK, ³University of Manchester, Manchester, UK

PR4 - 5. THE EFFECT OF NEUROPATHIC PAIN ON HEALTH STATUS, WORK PRODUCTIVITY LOSS, AND HEALTH CARE RESOURCE USE IN JAPAN

DiBonaventura MD¹, Fukuda T², Stankus A^3
1Kantar Health, New York, NY, USA, ²National Institute of Public Health, Saitama, Japan, ³Kantar Health, Princeton, NJ, USA

RM2: LACK OF STANDARDIZED METHODS FOR HANDLING MULTIPLES SOURCES FOR MODEL PARAMETERS: A SYSTEMATIC REVIEW

Rodrigo Antonini Ribeiro, IATS & HTAnalyze, Porto Alegre, Brazil

CE2: EVALUACIÓN DE LA COSTO-EFECTIVIDAD DE LA PRUEBA DE SECUENCIACIÓN COMPLETA DEL GEN CFTR POR TÉCNICA SANGER PARA PORTADORES ASINTOMÁTICOS EN POBLACIÓN COLOMBIANA DE PRIMER, SEGUNDO Y TERCER GRADO DE CONSANGUINIDAD CON HISTORIA FAMILIAR DE FIBROSIS QUÍSTICA. 

Ernesto Andrade, Universidad Nacional de Colombia, Bogota, Colombia

HT4: DEVELOPING AND PILOTING A VALUE FRAMEWORK AND A TOOL TO INFORM THE "EVIDENCE-TO-DECISION MAKING" PROCESS

Ernesto Andrade, Universidad Nacional de Colombia, Bogota, Colombia

HT4: DEVELOPING AND PILOTING A VALUE FRAMEWORK AND A TOOL TO INFORM THE "EVIDENCE-TO-DECISION MAKING" PROCESS

Andrea Alcaraz, Institute for Clinical Effectiveness and Health Policy (IECS), CABA, Argentina

RM4: DETERMINING THE BRAZILIAN POPULATION HEALTH STATUS: ESTIMATE OF HEALTH PRODUCTION FUNCTION

José Rodrigo Gobi, Universidade Estadual de Maringá, Maringá-PR, Brazil

CA4: COMPARISON OF THE ASSESSMENTS AND RECOMMENDATIONS ISSUED BY BRAZIL'S CONITEC AND CANADA'S CADTH FOR SELECT ONCOLOGY DRUGS

Jonas Montilva, Navigant Consulting, London, UK

CE1: COST-UTILITY ANALYSIS (CUA) OF TARGETED INTRAOPERATIVE RADIOTHERAPY ALONE (TARGIT-A) IN THE BRAZILIAN EARLY BREAST CANCER PATIENTS

Anil Vaidya, University of Alberta, Edmonton, AB, Canada

PP2 - AN EQ-5D-5L VALUE SET BASED ON URUGUAYAN POPULATION PREFERENCES: REPORT OF THE FIRST EXPERIENCE IN LATIN AMERICA

Augustovski F¹, Rey-Ares L¹, Irazola V¹, Garay U¹, Gianneo O², Fernandez G², Morales MR², Gibbons L¹, Ramos-Goñi JM^3
1Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina, ²Fondo Nacional de Recursos, Montevideo, Uruguay, ³The EuroQol Group Foundation, Rotterdam, The Netherlands

RM3 - COMPARISON OF SOCIAL EQ-5D TIME TRADE-OFF VALUES IN CHILE 2008-2013: DO GEOGRAPHICAL DIFFERENCES REALLY MATTER? 

Zárate V¹, Kind P², Valenzuela P^3
1Ministerio de Salud, Santiago, Chile, ²HSE University, St Petersburg, Russia, ³Datavoz, Santiago, Chile

PP4 - AN UNDEVELOPED PICTURE: THE AVAILABILITY OF UTILITY VALUATIONS IN LATIN AMERICA – HOW WILL THEY AFFECT QALYS?

Montgomery S¹, Stewart G², Kusel J^1
1Costello Medical Consulting Ltd, Cambridge, UK, ²Costello Medical Consulting Ltd., Cambridge, UK

MD1 - EVALUACIÓN ECONÓMICA DEL CARDIO-DESFIBRILADOR IMPLANTABLE COMPARADO CON LA TERAPIA FARMACOLÓGICA OPTIMA PARA EL TRATAMIENTO DE LOS PACIENTES CON FALLA CARDIACA EN COLOMBIA

Atehortua SC¹, Castro P¹, Ceballos M², Senior JM¹, Saldarriaga C¹, Giraldo N^1
1Universidad de Antioquia, Medellín, Colombia, ²Instituto de Evaluación Tecnológica en Salud (IETS), Bogotá, Colombia

CV4 - ECONOMICS OF DIABETES MELLITUS: THEORY AND EVIDENCE FOR BRAZILIAN DATA IN 2008

Balbinotto G, Wiest R, Jacinto P
Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil

CE1 - COST-EFFECTIVENESS ANALYSIS FOR CERVICAL CANCER SCREENING USING HPV TESTS IN CHILE

Franco Figueira S¹, Cachoeira CV¹, Souza FH¹, Kano BY¹, Silva M², Poulios N^3
1Roche Diagnostics LATAM, São Paulo, Brazil, ²Roche Diagnostics Chile, Santiago, Chile, ³Roche Molecular Systems, Inc., Pleasanton, CA, USA

CV2 - ESTIMATION OF THE COST-EFFECTIVENESS OF APIXABAN IN NON-VALVULAR ATRIAL FIBRILLATION IN ARGENTINA 

Giorgi MA¹, Caroli C², Micone P³, Giglio ND⁴, Aiello EC⁵, Donato BMK⁶, Mould JF⁷, Radero G⁸, Casas M^8
1CEMIC, Buenos Aires, Argentina, ²FLENI, Buenos Aires, Argentina, ³Universidad Austral, Buenos Aires, Argentina, ⁴Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina, ⁵Bristol-Myers Squibb, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Wallingford, CT, USA, ⁷Pfizer, Inc., New York, NY, USA, ⁸Pfizer, Inc., Buenos Aires, Argentina

CV3 - PULSE PRESSURE AND STROKE RISK: DEVELOPMENT AND VALIDATION OF A STROKE RISK EQUATION

Ayyagari R¹, Vekeman F², Lefebvre P², Ong SH³, Faust E¹, Trahey A¹, Machnicki G⁴, Duh MS^1
1Analysis Group, Inc., Boston, MA, USA, ²Groupe d’analyse, Ltée, Montréal, QC, Canada, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Latin America & Canada, Buenos Aires, Argentina

BU4 - BUDGET IMPACT ANALYSIS OF ABIRATERONE ACETATE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS PREVIOUSLY TREATED WITH DOCETAXEL FROM THE PERSPECTIVE OF THE BRAZILIAN PRIVATE HEALTH CARE SYSTEM

Vitale V, Asano E, Pereira ML
Janssen Cilag Farmaceutica, São Paulo, Brazil

FD3 - ¿PUEDE UN CAMBIO DEL 2003 EN EL REGLAMENTO EN EL CUADRO BÁSICO (CBM) EN MÉXICO IMPACTAR LA CANTIDAD DE ESTUDIOS CIENTÍFICOS PUBLICADOS DE EVALUACIÓN ECONÓMICA COMPLETOS DE MEDICAMENTOS (EECM) EN LOS ÚLTIMOS 10 AÑOS?

Márquez Cruz M¹, Peralta Bácenas LA¹, Ibarra Cázares AE¹, Rodriguez Mendoza MM¹, Pizarro Castellanos M², Soto Molina H^1
1Universidad Autónoma Metropolitana, México D.F., Mexico, ²Hospital Infantil Federico Gomez, México D.F., Mexico

TR1 - SELF-REPORTED HEALTH STATUS AND EQ-5D-3L VALUES OF THE ARGENTINE POPULATION: COMPARING 2005 VERSUS 2009 NATIONAL RISK FACTOR SURVEYS

Augustovski F, Rey Ares L, Gibbons L
Institute for Clinical Effectiveness and Health Policy (IECS), Buenos Aires, Argentina

CV4 - ANÁLISIS DE COSTO-EFECTIVIDAD DEL USO DE ESTATINAS EN LA PREVENCION DE EVENTOS CARDIOVASCULARES EN COLOMBIA

Mould J¹, Ordoñez J², Gutierrez-Ardila MV³, Vargas Zea N^3
1Pfizer, Inc., New York, NY, USA, ²Universidad CES, Medellin, Colombia, ³Pfizer S.A.S., Bogota, Colombia